Back to results
US 8,012,489 B2Granted
Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers
OwnerSteven Jones, Heinz Feldmann +1inventors
InventorsSteven Jones, Heinz Feldmann, Ute Stroeher
Life of this patent
Estimating the term…
Abstract
Recombinant VSV viral particles and the use thereof as vaccines for immunization are described.
Claims6
A vaccine comprising:
- a live, replication-competent recombinant vesicular stomatitis virus (VSV) particle comprising a nucleic acid molecule encoding a viral hemorrhagic fever (VHF) glycoprotein selected from the group consisting of a glycoprotein from Lassa virus;
- a glycoprotein from Marburg virus;
- and a glycoprotein from Ebola virus, inserted into the viral genome wherein the foreign glycoprotein has replaced the native VSV glycoprotein and only the VHF glycoprotein is expressed on the surface of the recombinant VSV particle, wherein said recombinant VSV particle is infectious.
A method of vaccinating an individual comprising:
- administering to an individual a live, replication competent recombinant vesicular stomatitis virus (VSV) particle comprising a nucleic acid molecule encoding a viral hemorrhagic fever (VHF) glycoprotein selected from the group consisting of a glycoprotein from Lassa virus;
- a glycoprotein from Marburg virus;
- and a glycoprotein from Ebola virus, inserted into the viral genome wherein the foreign glycoprotein has replaced the native VSV glycoprotein and only the VHF glycoprotein is expressed on the surface of the recombinant VSV particle, wherein said recombinant VSV particle is infectious and simulates infection by said VHF virus but does not cause disease or symptoms associated with said VHF.
Dependencies are inferred from the claim text.